Sunesis appoints Joseph DePinto as Chief Commercial Officer Sunesis Pharmaceuticals (SNSS) announced the appointment of Joseph DePinto to the newly created position of executive vice president and Chief Commercial Officer. Prior to joining Sunesis, DePinto was Executive Vice President, Global Commercial Operations at Dendreon (DNDN).
News For SNSS;DNDN From The Last 14 Days
Check below for free stories on SNSS;DNDN the last two weeks.
Sunesis volatility elevated into data from trial Sunesis overall option implied volatility of 298 is above its 26-week average of 156 according to Track Data, suggesting large price movement ahead of the upcoming release of data from a trial of its Qinprezo drug that is expected in the coming weeks.